Berzosertib
As of the edition of 20 October 2026, Berzosertib is a small molecule: in active development; acts on ATR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2020
- Kind
- Small molecule
- Registered trials
- 23, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Hormones; Urinary and reproductive; Nervous system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ATR | Serine/threonine-protein kinase ATR | Q13535 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 11 | 6 | 5 | 0 |
| Phase 2 | 12 | 5 | 7 | 0 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2012 to now |
| Merck Healthcare KGaA | Lead sponsor of trials | 2022 to now |